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RESPONSE BIAS AMONG LIKELY CLINICAL 
TRIAL PARTICIPANTS
McDonnell DD, Donohue JA
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To understand the demographic, attitudi-
nal, behavioral, and clinical characteristics of people who
are likely to participate in clinical trials. METHODS:
Analyses were based on a 12-page questionnaire mailed
to U.S. adults in 2000. A total of 21,986 responses were
received. Respondents were nationally representative
based on gender, age, race, and geographic region; results
were subsequently weighted and projected to the U.S.
population. Participants were asked if they had ever par-
ticipated in a clinical trial and whether they would ever
consider participating in one. RESULTS: Among those
who never participated in a clinical trial, 33% said they
would strongly consider participating in the future. This
group differed in some dramatic ways from the 26% who
said they would definitely not consider participating in a
clinical trial. For example, those who would participate
were more likely to be female (55% v. 49%), younger
(43 v. 47 years), and white (77% v. 70%). Behaviorally,
likely participants were more likely to drink alcohol
(64% v. 55%), smoke (27% v. 22%), visit physicians
(4.0 v. 3.6 visits in six months), and use the internet for
health care information (13% v. 6%). Attitudinally,
those willing to participate were more likely to harbor al-
ternative health care attitudes (e.g., “would try acupunc-
ture” 38% v. 17%) and less likely to be satisfied with
their current medical care (39% v. 47%). Clinically, they
were more likely to be diagnosed with a range of comor-
bid medical conditions such as depression (15% v. 6%),
migraines (16% v. 8%), and nasal allergies (32% v.
21%). CONCLUSION: People who are likely to partici-
pate in clinical trials look, think, and behave differently
than those who are not likely to participate. Trail design
and analysis should consider these differences and their
possible impact on clinical, economic, and humanistic
outcomes.
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OBJECTIVE:
 
 It is well documented that resource con-
sumption and costs vary across settings. Unit costs can
also vary. Using consistent cost-finding methods across
and within five Western European (WE) countries unit
costs of cardiovascular procedures were compared to ex-
amine the degree and impact of variation. METHODS:
Unit cost data were collected from fee schedules, national
averages and selected individual institutions. A bottom-
up costing approach was used in hospitals based upon a
definition of resources consumed for procedures. Hospi-
tal daily rates were calculated from an allocation of over-
head accounts and a basic package of services such as
nursing, housekeeping, dietary and pharmacy services.
Costs were obtained in the local currency and converted
directly to Euros. RESULTS: Unit cost variation was ob-
served within and across countries. UK costs for percuta-
neous transluminal coronary angioplasty (PTCA) in 13
centers ranged between 1380 and 2700 Euros, 0.75–1.5
times the median. Inter-country cost variation for the
same procedure ranged between 1850–4000 Euros, 0.60–
1.3 times the median. Daily hospital general ward rates
vary inter-country between 0.8 and 1.6 times the median,
comparable to within country variation. Physician ambu-
latory visit costs from fee schedules that may not reflect
actual costs were standard within country but varied
across countries (0.5–1.2 times the median of 18 Euros).
When applied to a consistent set of resources, differences
in costs resulted in widely varying cost-effectiveness (CE)
ratios by country. CONCLUSIONS: Obtaining compara-
ble unit costs within countries is difficult. Center-specific
costing is most reliable, but expensive and must be repre-
sentative for submissions to national level health authori-
ties. With standardized costing methods, the differences
observed here cannot be explained by differences in ac-
counting. Extreme care must be taken when transferring
the results of CE analyses between centers, especially be-
tween countries.
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OBJECTIVES: Airline passengers are particularly vulner-
able to the effects of cardiac arrest due to a lack of access
to emergency medical services. To offset this isolation,
airlines are installing automated external defibrillators
(AEDs) on aircraft. Our objective was to measure the
cost-effectiveness of airline AED programs and estimate
their value to the flying public. METHODS: A decision
analytic model was constructed to estimate the clinical
and economic effects of airline AEDs. Inputs were ob-
tained from published data and the FAA. Utility esti-
mates were derived from cardiac arrest survivors. Sensi-
tivity analyses evaluated changes in AED cost and
probability of cardiac arrest. Since AEDs may provide
utility gains through “peace of mind” for passengers not
experiencing a medical event, the impact of this added
passenger confidence was also evaluated. RESULTS:
AEDs on commercial aircraft cost an incremental $5.16
per flight. AED deployment resulted in an estimated ad-
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ditional $162,000 per QALY gained (16 quality-adjusted
minutes per flight). Sensitivity analysis of event proba-
bilities and cost inputs did not substantially change the
results. However, the cost-effectiveness of AEDs was sig-
nificantly enhanced by the inclusion of utility gain experi-
enced by passengers from increased peace of mind. While
the magnitude of this benefit is unknown, an incremental
increase of .003 in utility over the flight duration would
reduce the incremental cost-effectiveness of AEDs to less
than $50,000 per QALY gained. CONCLUSIONS: Our
model estimated that when the benefits of on-board
AEDs are limited to patients experiencing medical events,
the incremental cost-effectiveness is inferior to most rec-
ommended medical interventions. However, if passengers
gain utility from knowing an AED is on the aircraft, then
these incremental expenditures may be justified. Utility
gains from “peace of mind” may have significant impli-
cations in determining the value of health care interven-
tions. Further research should be conducted into this po-
tentially important area.
 
MD2
 
ANALYSIS OF THE IMPACT OF ASSISTIVE 
LIVING DEVICES ON SELF-ASSESSED HEALTH 
STATUS RATING
Rodney AB, Xiao H, Robertson T
Florida A&M University, Tallahassee, FL, USA
OBJECTIVE: Persons with limitations in Activities of
Daily Living (ADLs) generally report a greater sense of
independence when they have the use of assistive devices.
Insurance companies have traditionally been reluctant to
cover the cost of such devices, considering them to be
non-essential equipment. Although the economic cost
savings associated with a decrease in the need for exter-
nal caregivers and institutionalization are calculable, the
psychological benefits arising from this greater degree of
independence seen in patients who use assistive devices
tends to be overlooked. Therefore the main objective of
this project was to determine the impact of assistive living
devices on patients self-rated health status. METHOD:
Medical Expenditure Panel Survey (MEPS) Household
Component file 1998 P2R3/P3R1 was utilized for this
project. The initial pool of 25,000 cases was narrowed
using the inclusion criteria whereby all subjects must be
65 years or older, and have coded that they possessed one
or more physical disabilities or limitations. This led to a
final sample size of 1,025. Information on demographics,
socioeconomic status and level of disability was extracted
from the database for these patients. Multiple regression
analysis was conducted with self-rating of health status
serving as the dependent variable. The primary indepen-
dent variable of interest was use or non-use of assistive
living devices. Secondary independent variables included:
marital status, sex, age, race, educational level, physical
disabilities and limitations, and social limitations. RE-
SULTS: Use of assistive devices, race, age, some forms of
physical limitations and levels of education were signifi-
cant in this model (p  0.05). Marital status and gender
proved to be insignificant factors. CONCLUSIONS: Use
of assistive devices does have an impact on the way in
which individuals with limitations and disabilities view
their health status and therefore may be important con-
tributors to their overall quality of life.
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THE DIAGNOSTIC ACCURACY OF 18FDG-PET 
IN PATIENTS WITH RECURRENT PAPILLARY OR 
FOLLICULAR THYROID CANCER:
A SYSTEMATIC REVIEW
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OBJECTIVES.
 
 Positron Emission Tomography with 18F-
fluorodeoxyglucose (FDG-PET) is a new nuclear imaging
technique that can detect recurrent or metastatic thyroid
carcinomas. We conducted a systematic review to deter-
mine the diagnostic accuracy of FDG-PET in patients
with papillary and follicular thyroid carcinoma. METH-
ODS. Two unblinded reviewers independently selected,
extracted and assessed data from relevant literature. In-
cluded studies were prospective or retrospective with 10
human subjects or more that evaluated the accuracy of
FDG-PET in follicular and papillary thyroid cancer. Re-
views, case reports, editorials, letters, and comments
were excluded. The methodological quality of the in-
cluded studies was assessed by the criteria for diagnostic
tests recommended by the Cochrane Methods Group on
Screening and Diagnostic Tests. A qualitative analyse was
conducted to assess the value of FDG-PET in thyroid car-
cinoma. The rating system consisted of four levels of sci-
entific evidence (1  best; 4  worst). RESULTS. Two of
the fourteen included studies were considered of level 3
evidence. The other twelve studies provided level 4 evi-
dence. Most prevalent methodological flaws regarded va-
lidity of reference tests and blinding of test interpretation.
The overall conclusion in these studies was that FDG-
PET appeared beneficial in patients with elevated thyro-
globulin levels and negative 131I WBS. CONCLUSIONS.
In conclusion, although FDG-PET may solve clinical prob-
lems in selected patients suspected of recurrent thyroid
cancer, the present evidence does not allow for imple-
mentation of a routine diagnostic algorithm. Future stud-
ies should be designed to avoid the limitations presented
in this review.
 
MD4
 
INCLUSION OF INDIRECT COST IN ECONOMIC 
OUTCOMES ANALYSES OF MEDICAL DEVICES: 
HOW IMPORTANT IS IT?
Subramanian S, Justason BJ
Boston Scientific Corporation, Natick, MA, USA
OBJECTIVE: To evaluate the impact of indirect cost
(due to absence from work, disability, mortality) in eco-
nomic evaluations comparing minimally invasive proce-
